Table 1.
Study patients' characteristics
| All n = 157 | Systemic lupus erythematosus 35 (22.3%) | Rheumatoid arthritis 36 (22.9%) | B27-ankylosing spondylitis 22 (14.0%) | Psoriatic arthritis 40 (25.5%) | Giant cell arteritis 24 (15.3%) | p value | ||
|---|---|---|---|---|---|---|---|---|
| Sex—Female | 100 (63.7%) | 31 (88.6%) | 30 (83.3%) | 10 (45.5%) | 13 (32.5%) | 16 (66.7%) | < 0.0001 | |
| Age at third dose of SARS-CoV-2 vaccine | 58.8 (33.5, 88.2) | 53.3 (34.9, 83.0) | 64.5 (47.4, 74.1) | 51.9 (33.5, 75.5) | 58.3 (39.4, 88.2) | 75.6 (55.9, 83.9) | < 0.0001 | |
| Sample post-third SARS-CoV-2 provided | 110 (70.1%) | 20 (57.1%) | 32 (88.9%) | 17 (77.3%) | 23 (57.5%) | 18 (75.0%) | 0.0105 | |
| Treatment type | Not treated or Glucorticoids only | 25 (15.9%) | 10 (28.6%) | 0 (0.0%) | 7 (31.8%) | 0 (0.0%) | 8 (33.3%) | < 0.0001 |
| Non-biological | 48 (30.6%) | 17 (48.6%) | 8 (22.2%) | 0 (0.0%) | 16 (40.0%) | 7 (29.2%) | ||
| Biological | 69 (43.9%) | 8 (22.9%) | 18 (50.0%) | 15 (68.2%) | 19 (47.5%) | 9 (37.5%) | ||
| JAK-inhibitors | 15 (9.6%) | 0 (0.0%) | 10 (27.8%) | 0 (0.0%) | 5 (12.5%) | 0 (0.0%) | ||
| Glucocorticoids use | 43 (27.4%) | 7 (20.0%) | 11 (30.6%) | 0 (0.0%) | 7 (17.5%) | 18 (75.0%) | < 0.0001 | |
| mRNA-based vaccine type | mRNA-1273 | 100 (63.7%) | 25 (71.4%) | 30 (83.3%) | 18 (81.8%) | 25 (62.5%) | 2 (8.3%) | < 0.0001 |
| BNT162b2 | 57 (36.3%) | 10 (28.6%) | 6 (16.7%) | 4 (18.2%) | 15 (37.5%) | 22 (91.7%) | ||
| 2nd SARS-CoV-2 vaccine dose—baseline time interval (months) | 5.3 (2.3, 7.6) | 3.5 (2.3, 5.5) | 5.3 (4.4, 7.0) | 5.5 (3.4, 7.3) | 5.4 (4.2, 7.0) | 5.7 (4.9, 7.6) | < 0.0001 | |
| 3rd SARS-CoV-2 vaccine dose—follow-up time interval (months) | 3.8 (2.2, 7.0) | 4.0 (2.8, 7.0) | 3.6 (2.5, 7.0) | 4.1 (2.7, 6.9) | 3.5 (2.2, 5.4) | 4.5 (2.9, 6.5) | 0.1488 | |
| 2nd to 3rd dose of the SARS-CoV-2 vaccine time interval (months) | 6.7 (3.6, 11.1) | 6.8 (3.6, 11.1) | 6.7 (5.0, 8.5) | 6.8 (5.3, 8.7) | 6.8 (5.6, 10.0) | 6.9 (5.9, 8.6) | 0.2615 | |